“Suvorexant and Sleep's Benefits to Therapeutic Exposure for Posttraumatic Stress Disorder”
The purpose of this study is to examine effects of blocking the orexin system with suvorexant after exposure-based intervention for posttraumatic stress disorder (PTSD) on sleep, PTSD symptoms, and intersession habituation.
Drug - suvorexant
First in class orexin antagonist approved by the FDA for the treatment of insomnia
Pill with inactive ingredients
Can Blocking the Orexin System Enhance Sleep's Benefits to Therapeutic Exposure for PTSD?